Cecilia Brown

Lung Cancers Today

The US Food and Drug Administration has approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor.
The efficacy of ensartinib was evaluated in eXALT3, an open-label, randomized, active-controlled, multicenter trial that included 290 patients with locally advanced or metastatic ALK-positive NSCLC who had not previously received an ALK-targeted therapy. Patients were randomized 1:1 to receive either ensartinib or crizotinib.
The main efficacy outcome measure was progression-free survival (PFS) as evaluated by a blinded independent central review. The key secondary efficacy outcome measure was overall survival (OS).
Ensartinib showed a statistically significant PFS improvement compared to crizotinib with a median PFS of 25.8 months (95% CI, 21.8 to not estimable) compared with a median PFS of 12.7 months in patients receiving crizotinib (95% CI, 9.2 to 16.6), with a hazard ratio (HR) of 0.56 (95% CI, 0.40-0.79; P = .0007).
The most common adverse reactions, occurring in at least 20% of patients, were rash, musculoskeletal pain, constipation, cough, pruritus, nausea, edema, pyrexia, and fatigue. The recommended ensartinib dose is 225 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
Source: <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ensartinib-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer">FDA </a>

The US Food and Drug Administration has approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor.The efficacy of ensartinib was evaluated in eXALT3, an open-label, randomized, active-controlled, multicenter trial that included 290 patients with locally advanced or metastatic ALK-positive NSCLC who had not previously received an ALK-targeted therapy. Patients were randomized 1:1 to receive either ensartinib or crizotinib.The main efficacy outcome measure was progression-free survival (PFS) as evaluated by a blinded independent central review. The key secondary efficacy outcome measure was overall survival (OS).Ensartinib showed a statistically significant PFS improvement compared to crizotinib with a median PFS of 25.8 months (95% CI, 21.8 to not estimable) compared with a median PFS of 12.7 months in patients receiving crizotinib (95% CI, 9.2 to 16.6), with a hazard ratio (HR) of 0.56 (95% CI, 0.40-0.79; P = .0007).The most common adverse reactions, occurring in at least 20% of patients, were rash, musculoskeletal pain, constipation, cough, pruritus, nausea, edema, pyrexia, and fatigue. The recommended ensartinib dose is 225 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.Source: <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ensartinib-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer">FDA </a>

Millie Das, MD

Martin Dietrich, MD, PhD

Stephen V. Liu, MD

Eric Singhi, MD

Community Oncology Insights: Panel Discusses Molecular Testing Approaches, Barriers

Expert Interviews

Molecular Testing in Lung Cancer: Experts Review Progress, Challenges

Pasi A. Jänne, MD, PhD

FLAURA2 Principal Investigator Shares Insights on Final OS Analysis

EGFR+ NSCLC

The Changing Face of Lung Cancer: Experts Discuss the Rising Incidence in Young Adults

Phase 3 FLAURA2 Trial: Final OS Analysis Shows Significant OS Improvement With Osimertinib Plus Chemotherapy for EGFR-Mutated NSCLC

Jill Feldman

Laura Litwin

COCOON: Jill Feldman Discusses the Importance of Patient Advocacy in Clinical Trials

ASCO 2025

Latest News

FDA Approves Ensartinib for ALK-Positive Locally Advanced or Metastatic NSCLC

ALK+ NSCLC

The U.S. Food and Drug Administration has approved ensartinib (Ensacove) for adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.